Press Releases for Austria
Another Victory for SPI in Stolichnaya Trademark Dispute
16/02/2018 — LINZ, Austria — (BUSINESS WIRE) On February 5, 2018, in Linz, SPI Group achieved yet another significant legal victory in its long-running dispute with Russian state-owned entity Federal […]
Samsung Electronics and TTTech Announce Strategic Partnership to Deliver Next Generation of Autonomous and Safety Technology to Automakers
Samsung to join AUDI AG as a major investor in TTTech, which will develop new open-innovation platform for ADAS/AV systems; HARMAN to integrate this open platform offering to its innovative […]
MSD Animal Health to Purchase Manufacturing Facility in Krems, Austria
European Facility Will Boost Global Vaccine Production Capacity 08/08/2017 — MADISON, N.J. — (BUSINESS WIRE) MSD Animal Health, known as Merck Animal Health in the United States and Canada, today […]
Physio-Control Launches LIFEPAK® CR2 Defibrillator
New LIFEPAK AED Response System Offers Connectivity, Intuitive Design and Unique Technology to Analyse Heart Rhythm during CPR New AED Solution to be Exhibited at MEDICA 2016, November 14-17 02/11/2016 […]
UniCredit Bank Austria, Raiffeisen Bank International and UniCredit Bulbank Granted an Expanded € 112.9 Million Senior Facility to Business Park Sofia
20/10/2016 — VIENNA, Austria & SOFIA, Bulgaria — (BUSINESS WIRE) UniCredit Bank Austria AG and UniCredit Bulbank AD increased and amended its current senior facility with Business Park Sofia (BPS), […]
New Data from KEYNOTE-028, MSD’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced new findings from the KEYNOTE-028 Phase 1b study, the clinical trial investigating the use of the company’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat cancers. Data from this trial, to be presented at the European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29, include the first-time findings for KEYTRUDA in two gastrointestinal cancers, advanced anal cancer and advanced biliary tract cancer, and add to MSD’s growing body of clinical data for KEYTRUDA.
New Findings Show Anti-Tumor Activity of KEYTRUDA® (pembrolizumab) in Patients with Advanced Nasopharyngeal Carcinoma
MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma (NPC) – a type of head and neck cancer – whose tumors express PD-L1 (≥1% of cells in tumor nests or PD-L1+ bands in stroma). Data were from a Phase 1b study (KEYNOTE-028) and showed an overall response rate (ORR) (confirmed and unconfirmed) of 22.2 percent (95% CI, 8.6-42.3) in evaluable patients (n=27) who were treated with KEYTRUDA. Results were presented in an oral session by Dr. Chiun Hsu, National Taiwan University Hospital, at the European Cancer Congress (ECC) in Vienna (Abstract #2801).
CEMEX Announces Divestment of Its Operations in Austria and Hungary
CEMEX, S.A.B. de C.V. (“CEMEX”) (NYSE: CX) announced today that it has signed an agreement for the sale of its operations in Austria and Hungary to the Rohrdorfer Group for approximately ˆ160.1 million.
UniCredit Bank Austria and UniCredit Bulbank Provide ˆ 103.3 Million Senior Facility to Business Park Sofia
UniCredit Bank Austria AG and UniCredit Bulbank AD have jointly underwritten a ˆ 103.3 million senior facility to refinance Business Park Sofia (BPS), the largest office park in Southeastern Europe. The transaction closed in June 2015.
MSD’s Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
MSD, known as Merck (NYSE:MRK) in the United States and Canada, announced today the first presentations of data from the company’s ongoing C-EDGE pivotal Phase 3 clinical trial programme evaluating the investigational once-daily tablet grazoprevir/elbasvir (100mg/50mg) in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6 (GT1, 4 or 6).1 Patients in both the HCV infected, treatment-naïve (C-EDGE TN), and HIV/HCV co-infected, treatment-naïve (C-EDGE CO-INFXN) trials treated for 12 weeks achieved rates of sustained virologic response 12 weeks after the completion of treatment (SVR12) of 95 percent (299/316 and 207/218, respectively). In addition, HCV infected, treatment-experienced patients (C-EDGE TE) treated with or without ribavirin (RBV) for 12 weeks achieved SVR12 rates of 94 percent (98/104) and 92 percent (97/105), respectively, and those treated for 16 weeks achieved SVR12 rates of 97 percent (103/106) and 92 percent (97/105), respectively. These data were presented at The International Liver CongressTM 2015 – the 50th annual congress of the European Association for the Study of the Liver (Abstract #G07, E-Poster P0886 and E-Poster P0887). A paper detailing the findings of C-EDGE TN was published online in the Annals of Internal Medicine today.